Triple-receptor agonism
Comparative study of simultaneous GLP-1, GIP, and glucagon receptor engagement.

All research products on this site, including all peptides, are sold strictly for laboratory and research use only, not for human or animal consumption, diagnostic, or therapeutic use. Our tallow skincare products are topical cosmetics. You must be 21 or older to enter.
By entering you confirm you are 21+ and accept these products are for research use only. See our Terms and Disclaimer.

For laboratory research. Sold in 10mg, 30mg, 30mg x 2, 100mg and 300mg kit sizes.
Complete the order
Supplies and compounds researchers add to this order
Identity, purity and handling data for this compound, in one place. Tap an identifier to copy it.
For research use only. Not for human consumption.
ORP-3(RT) is a synthetic peptide developed for laboratory research as a triple receptor agonist, meaning a single molecule engineered to bind and activate three distinct receptor targets rather than one. It is investigated in research models for activity at the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). Because all three receptors belong to the same proglucagon-derived peptide family, ORP-3(RT) is used by researchers to study how a single compound behaves across multiple related signaling pathways in one experimental system. It is supplied strictly for laboratory research use, not for human or animal consumption.
Research interest in ORP-3(RT) centers on its multi-receptor pharmacology. Each of the three receptors it engages, GLP-1R, GIPR, and GCGR, is a class B G protein-coupled receptor that signals primarily through adenylate cyclase and cyclic AMP production when activated. Laboratory studies on ORP-3(RT) examine receptor binding affinity, activation kinetics, and downstream second-messenger signaling at each receptor individually, as well as how simultaneous engagement of all three may alter the overall signaling profile compared to single-receptor activation.
As a triple receptor agonist, ORP-3(RT) is studied alongside single- and dual-receptor peptide analogs to characterize structure-activity relationships across the incretin and glucagon receptor family. Comparative in-vitro assays assess relative potency and selectivity at each receptor, while receptor internalization and desensitization studies explore how prolonged or repeated exposure affects receptor availability in cell-based systems. This research framework positions ORP-3(RT) as a reference compound for investigating multi-receptor agonism as a pharmacological strategy, distinct from mono-agonist peptides that target only one of these three receptors.
Because the GLP-1, GIP, and glucagon receptors are each implicated in distinct aspects of energy balance and glucose-regulatory signaling, ORP-3(RT) is used in preclinical and in-vitro research to map how combined activation of these pathways is coordinated at the cellular level. Studies in this area typically rely on isolated cell lines expressing one or more of the target receptors, as well as rodent models used to characterize receptor pharmacology and signaling cascades. This research is exploratory and mechanistic in nature, intended to inform the broader scientific understanding of multi-receptor incretin and glucagon-family biology.
ORP-3(RT) is distributed by Optimum ReGen Peptides for laboratory research. Review available batch reports and contact us for documentation on the specific product and lot before ordering.
ORP-3(RT) is supplied as a lyophilized, freeze-dried powder intended for reconstitution in a laboratory setting prior to use in cell-based or preclinical experimental protocols. Researchers should follow the storage and handling guidance provided with each shipment and accompanying certificate of analysis to preserve peptide stability between receipt and use.
ORP-3(RT) is sold exclusively for laboratory research use by qualified professionals and institutions. It is not approved, and not intended, for human or animal consumption, and no health or disease-related claims are made about it. This listing is provided for research and informational purposes only and does not constitute medical advice.
The areas where this compound appears in the published research literature.
In laboratory research, incretin and glucagon receptor peptides are typically studied using heterologous expression systems in which the relevant receptor is expressed in cell lines (e.g., HEK293 or CHO cells), and peptide binding and receptor activation are assessed via cAMP accumulation assays, radioligand binding, or BRET-based biosensors.
Preclinical metabolic studies use rodent models of glucose challenge or metabolic perturbation to assess effects on insulin secretion, energy expenditure, and substrate handling. ORP-3(RT) is of particular interest as a tool for comparing triple-pathway activity against single- and dual-agonist reference compounds.
Lyophilized research-grade peptides should be stored at -20 °C in a desiccated, sealed environment away from direct light. Reconstituted solutions should be prepared fresh in sterile aqueous buffer appropriate for the assay system and used promptly or stored at -80 °C in single-use aliquots.
Peptide stability in solution is influenced by pH, temperature, and solvent composition. Researchers should consult peptide-specific stability data and use the minimum number of freeze-thaw cycles to preserve structural integrity and biological activity in experimental preparations.
ORP-3(RT) for sale from Optimum ReGen Peptides, a US research-peptide company with a storefront in Medford, Oregon. It is in stock, priced from $75. Every order ships 2-Day Priority Air, a $13 flat rate anywhere in the US, with tracking, or can be picked up at the store.
The current batch has a published third-party certificate of analysis, shown above. ORP-3(RT) is supplied as lyophilized powder, for laboratory and research use only, not for human consumption.